Browse the evidence

Orlistat causes mechanism-specific gastrointestinal adverse effects (steatorrhea, fecal urgency, flatulence) due to fat malabsorption, but these are generally manageable with dietary modification.

If you take Orlistat, you may experience oily stools, gas, or urgency, especially if you eat high-fat meals. To minimize these effects, limit your fat intake and take vitamin supplements as recommended. These side effects are predictable and manageable, but they require dietary awareness.

Continuous Positive Airway Pressure (CPAP) therapy effectively improves daytime sleepiness and quality of life in Obstructive Sleep Apnoea (OSA) patients, but its impact on cardiometabolic outcomes is uncertain and secondary prevention trials have failed to demonstrate significant modification of cardiovascular events.

CPAP is the most effective treatment for stopping snoring and fixing daytime sleepiness in OSA patients. However, do not expect it to automatically fix your heart health or blood sugar levels, as evidence for those benefits is weak. If you struggle with the mask, talk to your doctor about alternatives like oral appliances or nerve stimulation, as adherence is a major hurdle.

GIP receptor (GIPR) antagonism enhances the weight-loss efficacy of GLP-1 receptor agonists by removing an inhibitory tone on central nervous system (CNS) satiety circuits, specifically within hindbrain GABAergic neurons.

If you are using a GLP-1 medication (like semaglutide or liraglutide) and experiencing significant side effects like nausea without sufficient weight loss, newer therapies that block the GIP receptor (antagonism) while activating GLP-1 may be more effective and tolerable. This works by removing a natural 'brake' on your brain's satiety signals, allowing the medication to work more efficiently.

Sedentary behavior exceeding 9 hours per day significantly increases the odds of hypertension and diabetes, with stronger associations observed in socioeconomically vulnerable populations (Basic Livelihood Security recipients) compared to non-recipients.

If you sit for more than 9 hours a day, your risk for high blood pressure and diabetes increases significantly, especially if you have limited income. To mitigate this, do not sit continuously for long periods. Break up your sitting time with light activity, such as standing or walking for a few minutes, as this improves blood sugar control and vascular health even if you do not have time for formal exercise.

Below-average intake of energy and carbohydrates is associated with increased odds of hypertension and diabetes in socioeconomically vulnerable populations, contradicting the assumption that low-calorie diets are universally protective.

For older adults with limited income, eating very little or avoiding carbohydrates may actually increase your risk of high blood pressure and diabetes. Ensure you are consuming adequate energy and carbohydrates from nutritious sources to support metabolic health, as deficiency in this group is linked to higher disease odds.

Using gender-specific portion sizes (GS-PS) in food frequency questionnaires improves the accuracy of absolute nutrient intake estimates compared to using common portion sizes, but does not improve the accuracy of nutrient density estimates.

If you are tracking your absolute nutrient intake (e.g., total grams of protein or calories) using a food diary or app, using gender-specific portion estimates can improve accuracy. However, if you are tracking nutrient density (e.g., percentage of calories from fat or protein), using standard portion sizes is likely sufficient as gender-specific adjustments do not significantly change these ratios.

Increasing dietary cholesterol intake to levels substantially above the previous 300 mg/day limit does not negatively impact LDL-C, HDL-C, or triglyceride levels when consumed within the context of a healthy, low-carbohydrate weight loss diet.

If you are following a healthy low-carbohydrate diet and losing weight, you do not need to restrict your cholesterol intake to 300 mg per day. Increasing your intake of cholesterol-rich foods like eggs, while reducing refined grains and sugars, does not appear to negatively affect your blood lipid levels (LDL, HDL, triglycerides). Focus on the overall quality of your diet rather than a specific cholesterol number.

Comprehensive obesity care requires the integration of behavioral health support to address weight stigma, disordered eating, and the psychosocial impacts of large magnitude weight loss, which medical management alone cannot resolve.

Obesity treatment involves more than just weight loss; it includes managing the psychological impact of the disease. Seek out behavioral health support to address weight stigma, disordered eating, and the emotional changes that come with significant weight loss.

Incretin-based therapies (GLP-1 and GLP-1/GIP RAs) induce substantial weight loss that is predominantly derived from fat mass, resulting in the relative preservation or improvement of lean body mass percentage and muscle quality, despite absolute reductions in lean mass.

If you are using GLP-1 or GLP-1/GIP medications for weight loss, expect to lose mostly fat. You will likely lose some muscle mass in absolute terms, but your body composition will improve because you are losing fat faster than muscle. To maximize this benefit, prioritize protein intake (1.2-1.6 g/kg/day) and engage in resistance training to signal your body to keep muscle tissue.

Physical activity and exercise provide significant health benefits for adults with overweight or obesity independent of weight loss, including improvements in body composition quality, cardiorespiratory fitness, and metabolic health.

Prioritize regular physical activity regardless of your current weight. Focus on building cardiorespiratory fitness and muscle strength, as these provide health benefits even if you do not lose weight. Do not let the absence of scale movement discourage you from exercising.

GLP-1 receptor agonists (semaglutide and tirzepatide) produce highly heterogeneous weight loss outcomes, with 'super responders' achieving >15% body weight loss while 'minimal responders' achieve <5%, driven by distinct pre-treatment clinical phenotypes rather than uniform biological response.

If you are taking a GLP-1 medication like Ozempic or Mounjaro, understand that your weight loss outcome is not guaranteed to be 'super' (>15% loss). Your pre-existing health conditions (like sleep apnea, psoriasis, or fibromyalgia) may predict how well you respond. Focus on the health benefits of even moderate weight loss (5-15%) rather than comparing yourself to 'super responder' statistics, as individual biology plays a massive role in the final result.

Pre-treatment clinical phenotypes, specifically the presence or absence of certain comorbidities, are strongly associated with the likelihood of being a 'super responder' to specific GLP-1RA brands.

Your existing health conditions might predict how well a specific weight-loss drug will work for you. For example, those without fibromyalgia or osteoarthritis might respond better to Zepbound, while those with psoriasis might respond better to Wegovy. Discuss your full medical history with your provider to help select the most appropriate GLP-1RA.

Tirzepatide (Zepbound/Mounjaro) is associated with a higher proportion of 'super responders' (>15% weight loss) compared to semaglutide (Ozempic/Wegovy) in real-world settings.

If you are choosing between GLP-1 medications, tirzepatide (Zepbound/Mounjaro) may offer a higher probability of 'super response' (>15% weight loss) compared to semaglutide (Ozempic/Wegovy). However, individual response varies, and your specific health profile should guide the choice.

GLP-1 receptor agonists and incretin co-agonists reduce total body weight primarily through adipose tissue loss, but this process involves an absolute reduction in lean mass (skeletal muscle) that typically accounts for 20–30% of the total weight lost.

If you are taking GLP-1 medications, expect to lose some muscle along with fat. To minimize this, prioritize resistance training and adequate protein intake. This helps preserve strength and metabolic health despite the inevitable lean mass reduction.

Dual-agonists targeting GLP-1 and Glucagon receptors (e.g., Mazdutide, Survodutide) offer superior weight loss and metabolic improvements compared to GLP-1 monotherapies, though they carry a higher risk of gastrointestinal adverse events.

Mazdutide is a once-weekly injection targeting both GLP-1 and Glucagon receptors. In trials, a 9mg dose led to an 18.6% average body weight loss over 48 weeks, outperforming many single-hormone drugs. However, patients should be aware of a higher rate of gastrointestinal side effects compared to some GLP-1 monotherapies, which may lead to discontinuation.

GLP-1 receptor agonists (GLP-1RAs) treat obesity by activating central and peripheral GLP-1 receptors to increase satiety, delay gastric emptying, and modulate energy expenditure, resulting in significant weight loss.

GLP-1 receptor agonists are a class of medications that mimic a gut hormone to signal fullness to the brain and slow digestion. They are prescribed for obesity and type 2 diabetes. Common examples include Semaglutide (Ozempic/Wegovy) and Liraglutide (Saxenda). These drugs require a prescription and often involve starting at a low dose to manage side effects like nausea. They are part of a long-term management strategy for obesity, not a quick fix.

GLP-1 receptor agonists (GLP-1 RAs) are displacing bariatric surgery as the primary obesity treatment in the US, evidenced by a 1451% increase in GLP-1 RA use and a 65% decline in bariatric surgery procedures.

GLP-1 medications are becoming the dominant obesity treatment in the US, largely replacing bariatric surgery in utilization trends. However, surgery remains a crucial option for severe obesity due to its durability, especially if GLP-1 medications are discontinued. Patients should discuss long-term adherence and potential side effects with their providers.

Tirzepatide significantly reduces the apnea-hypopnea index (AHI) and body weight in patients with moderate to severe obstructive sleep apnea (OSA) and obesity, regardless of whether they are using positive airway pressure (PAP) therapy.

If you have moderate to severe sleep apnea and obesity, Tirzepatide is a newly FDA-approved treatment that significantly reduces breathing interruptions during sleep and leads to substantial weight loss (18-20%). It works not just by shrinking fat around the airway, but also by reducing inflammation and affecting brain signals related to sleep. You can use it alone or alongside your CPAP machine. Because rapid weight loss can affect muscle, you should combine this medication with strength training and nutritional counseling.

GLP-1 receptor agonists (specifically Liraglutide) improve OSA outcomes when used in combination with CPAP, but CPAP alone is superior to Liraglutide monotherapy for reducing cardiovascular inflammation and plaque volume.

If you have severe sleep apnea and diabetes, adding Liraglutide to your CPAP therapy can further reduce breathing interruptions compared to using Liraglutide alone. However, CPAP is still necessary for protecting your heart and reducing arterial plaque, as Liraglutide alone does not provide this specific cardiovascular benefit. If you struggle with CPAP, discuss combination strategies with your doctor.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates rapidly increasing real-world utilization as both a glucose-lowering medication and an anti-obesity medication in patients with chronic kidney disease (CKD), with initiators showing high rates of obesity and morbid obesity.

For patients with CKD, tirzepatide is increasingly being used to manage both blood sugar and weight. Real-world data indicates that doctors are prescribing it more frequently, especially for those with obesity. While clinical trials have limited CKD representation, real-world usage is high and growing.

At higher doses (30% of energy), whey protein elicits a significantly greater insulinogenic response than soy protein, whereas at lower doses (15% of energy), both proteins produce similar insulin responses and have no differential effect on plasma glucose.

If you are healthy and normal weight, you can use either whey or soy protein for post-workout or meal supplementation without worrying about blood sugar spikes. At moderate amounts (around 15g protein), they behave the same. If you consume larger amounts (30g+), whey will trigger a higher insulin response than soy, but this did not negatively impact blood glucose levels in this study. For Asian Indians at higher risk for Type 2 Diabetes, moderate doses of either protein are equally effective for glucose homeostasis.

Long-term maintenance of cardiorespiratory fitness (CRF) improves insulin sensitivity in men with visceral obesity, even when visceral adipose tissue (VAT) rebounds.

Focus on maintaining your aerobic fitness (cardiorespiratory fitness) rather than obsessing over small fluctuations in body fat. If you maintain your fitness level, your body's ability to handle insulin remains high, even if you regain some visceral fat. Prioritize consistent physical activity over strict weight maintenance.

Reductions in intramuscular fat (specifically core and psoas low-attenuation muscle area) are associated with improved insulin resistance, independent of visceral fat changes.

Exercise helps reduce fat stored within muscles (intramuscular fat), which directly improves how your body uses insulin. This benefit occurs even if you don't lose all your belly fat.

Carbohydrate-restricted diets facilitate greater fat loss and weight loss maintenance in individuals with high insulin secretion or insulin resistance compared to low-fat diets, primarily by reducing hunger and preserving energy expenditure.

If you struggle with weight loss despite eating less, you may have high insulin levels. Try reducing carbohydrates (especially refined grains and sugars) without strictly counting calories. This approach may help control hunger and preserve energy expenditure, making it easier to lose fat and keep it off, especially if you have insulin resistance or type 2 diabetes.